13F Pro13F Pro

Catalio Capital Management, LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1958125
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare99.9%$531.7M
  • Other0.1%$367,950

AUM History

13fpro.ai/research/fund/catalio-capital-management-lp-1958125

Conviction and streaks

Concentrating · top 10 = 56.7%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

SNDX$SNDXConviction hold5.0% weight · held 6 quartersNTRA$NTRAConviction hold4.2% weight · held 5 quartersSEPN$SEPNConviction hold3.4% weight · held 7 quartersGPCR$GPCRConviction hold2.8% weight · held 7 quartersIRON$IRONConviction hold2.2% weight · held 5 quartersELDN$ELDNAccumulating+60% shares · 3 quarters runningNTRA$NTRAAccumulating+32% shares · 2 quarters runningMLYS$MLYSAccumulating+96% shares · 2 quarters runningHTFL$HTFLAccumulating+412% shares · 2 quarters runningGPCR$GPCRAccumulating+9% shares · 2 quarters runningDNTH$DNTHTrimming-96% shares · 5 quarters runningEW$EWTrimming-71% shares · 4 quarters runningTARA$TARATrimming-68% shares · 4 quarters runningBMY$BMYTrimming-36% shares · 2 quarters runningDYN$DYNTrimming-53% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/catalio-capital-management-lp-1958125

Catalio Capital Management, LP 13F holdings — Q2 2026

$532.1M portfolio (+11.2% QoQ) · 39 holdings · Q2 2026 13F · top 10 are 57% of the stock portfolio

All holdings — Catalio Capital Management, LP (Q2 2026)

39 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
SEPN$SEPNSepterna, Inc.$18.0M+82%
MLYS$MLYSMineralys Therapeutics, Inc.$17.5M+48%
HTFL$HTFLHeartflow, Inc.$17.1M+44%
CRVS$CRVSCorvus Pharmaceuticals, Inc.$16.1M+21%
GPCR$GPCRStructure Therapeutics Inc.adr$14.8M+8%
PTGX$PTGXProtagonist Therapeutics, Inc$13.1MNew
IRON$IRONDisc Medicine, Inc.$11.7M+30%
EW$EWEdwards Lifesciences Corp$11.3M-14%
AXSM$AXSMAxsome Therapeutics, Inc.$10.6MNew
RARE$RAREUltragenyx Pharmaceutical Inc.$10.6M-63%
KLRA$KLRAKailera Therapeutics, Inc.$10.3MNew
KPTI$KPTIKaryopharm Therapeutics Inc.$9.2M+5%
ODTX$ODTXOdyssey Therapeutics, Inc.$8.6MNew
ASND$ASNDAscendis Pharma A/S$8.5M-75%
KARD$KARDKardigan, Inc.$7.5MNew

What changed in Q2 2026

Against the previous quarter's 13F: 10 new, 15 added to, 9 trimmed, 12 sold out. Share-count changes; largest moves by dollar size first.

New positions (10)

  • AVLN$AVLNAvalyn Pharma Inc.$55.2M

    first bought this quarter

  • JNJ$JNJJOHNSON & JOHNSON$35.3M

    first bought this quarter

  • PBLS$PBLSParabilis Medicines, Inc.$22.6M

    first bought this quarter

  • PTGX$PTGXProtagonist Therapeutics, Inc$13.1M

    first bought this quarter

  • AXSM$AXSMAxsome Therapeutics, Inc.$10.6M

    first bought this quarter

  • KLRA$KLRAKailera Therapeutics, Inc.$10.3M

    first bought this quarter

+4 more in the Excel export

Added to (15)

  • GILD$GILDGILEAD SCIENCES, INC.+64%

    now $34.0M · held 3 qtrs

  • SEPN$SEPNSepterna, Inc.+82%

    now $18.0M · held 7+ qtrs

  • MLYS$MLYSMineralys Therapeutics, Inc.+48%

    now $17.5M · held 3 qtrs, 3 adds in a row

  • HTFL$HTFLHeartflow, Inc.+44%

    now $17.1M · held 3 qtrs, 3 adds in a row

  • SNDX$SNDXSyndax Pharmaceuticals Inc+16%

    now $26.6M · held 6 qtrs

  • NTRA$NTRANatera, Inc.+16%

    now $22.3M · held 5 qtrs, 2 adds in a row

+9 more in the Excel export

Trimmed (9)

  • DNTH$DNTHDianthus Therapeutics, Inc. /DE/-94%

    now $3.2M · held 7+ qtrs, 5 trims in a row

  • ASND$ASNDAscendis Pharma A/S-75%

    now $8.5M · held 7+ qtrs

  • DFTX$DFTXDefinium Therapeutics, Inc.-46%

    now $26.5M · held 2 qtrs

  • RARE$RAREUltragenyx Pharmaceutical Inc.-63%

    now $10.6M · held 5 qtrs

  • MANE$MANEVeradermics, Inc-74%

    now $5.6M · held 2 qtrs

  • EW$EWEdwards Lifesciences Corp-14%

    now $11.3M · held 3 qtrs, 2 trims in a row

+3 more in the Excel export

Sold out (12)

  • TERN$TERNTerns Pharmaceuticals, Inc.was $21.6M

    held 2 qtrs

  • SLNO$SLNOSOLENO THERAPEUTICS INCwas $19.3M

    held 5 qtrs

  • BSX$BSXBOSTON SCIENTIFIC CORPwas $18.8M

    held 4 qtrs

  • CYTK$CYTKCYTOKINETICS INCwas $14.2M

    held 6+ qtrs

  • ADPT$ADPTAdaptive Biotechnologies Corpwas $10.0M
  • KALV$KALVKalVista Pharmaceuticals, Inc.was $8.6M

+6 more in the Excel export

Firm AUM (Form ADV): $2.2B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Catalio Capital Management, LP has filed, 6 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Catalio Capital Management?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Catalio Capital Management's top 20 holdings: 52/100 (our AI quality score, weighted by position size; 13 of the 20 are scored)

Top 10 since filing

-10.6%

Value-weighted move of the 10 largest stock positions

Turnover

44%

Last quarter; 150% over the last 4

Top 10 weight

57%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

27%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Catalio Capital Management, LP disclosed 39 positions worth $532.1M in its Form 13F-HR for Q2 2026, led by $AVLN (Avalyn Pharma Inc.) at 10.4% of the equity portfolio, followed by $JNJ and $GILD. During the quarter the fund opened 10 new positions and exited 12 — including a new stake in $AVLN and a full exit from $TERN. The portfolio is most concentrated in Healthcare (99.9% of disclosed assets). All figures are sourced directly from Catalio Capital Management, LP’s Form 13F-HR filing with the SEC under CIK 1958125.

Funds like this

managers whose biggest positions overlap Catalio Capital Management's
RA CAPITAL MANAGEMENT, L.P.$11.51B 13F book · 6 shared top holdingsPBLSSEPNMLYSIRONFARALLON CAPITAL MANAGEMENT LLC$21.68B 13F book · 4 shared top holdingsBBIONTRAPTGXPBLSSofinnova Ventures Inc$1.93B 13F book · 9 shared top holdingsNTRABMYGILDAXSMBellevue Group AG$4.75B 13F book · 7 shared top holdingsGILDBBIOEWRARERTW INVESTMENTS, LP$11.71B 13F book · 6 shared top holdingsPTGXNTRARAREKLRASR ONE CAPITAL MANAGEMENT, LP$1.04B 13F book · 5 shared top holdingsAVLNMLYSODTXMANE

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Catalio Capital Management, LP

13F Pro is an AI hedge fund tracker and stock research platform. For Catalio Capital Management, LP (SEC CIK: 1958125), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Catalio Capital Management, LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.